 |
|
Optimal Digoxin Concentrations for Patients With Heart Failure
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: We have 2 concerns about the study of Mr Rathore and colleagues.1 First, about 70% of ingested digoxin is eliminated renally.2 Nonetheless, the small differences in glomerular filtration rate and in dosing between the 3 digoxin groups reported by Rathore et al, although statistically significant, certainly do not explain the more than 2-fold increase in SDCs between groups.
Second, P-glycoprotein has been shown to have a major role in digoxin pharmacokinetics.3 P-glycoprotein, a xenobiotic transport protein located in the intestine, liver, kidney, and other tissues, influences drug absorption and elimination.3 Drugs that inhibit the activity of P-glycoprotein have been shown to increase SDCs.3 Amiodarone, an antiarrhythmic agent commonly used in the prevention of recurrent ventricular arrhythmias in patients with heart failure,4 approximately doubles SDCs by inhibiting P-glycoprotein transport.5 Because Rathore et al did not provide data on prior on antiarrhythmic use or prior history of ventricular arrhythmias, . . . [Full Text of this Article]
RELATED ARTICLES
Optimal Digoxin Concentrations for Patients With Heart Failure
Pierugo Carbonin and Giuseppe Zuccalà
JAMA. 2003;289(20):2643.
EXTRACT
| FULL TEXT
Optimal Digoxin Concentrations for Patients With Heart Failure—Reply
Saif S. Rathore, Jeptha P. Curtis, Yongfei Wang, Michael R. Bristow, and Harlan M. Krumholz
JAMA. 2003;289(20):2643-2644.
EXTRACT
| FULL TEXT
Association of Serum Digoxin Concentration and Outcomes in Patients With Heart Failure
Saif S. Rathore, Jeptha P. Curtis, Yongfei Wang, Michael R. Bristow, and Harlan M. Krumholz
JAMA. 2003;289(7):871-878.
ABSTRACT
| FULL TEXT
|
